ArticleFrontiers in neurology2025
Stage-specific efficacy of pharmacological interventions on gait impairments in Parkinson's disease.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to clarify the variations and the therapeutic effects of medicine on gait by analyzing the gait characteristics before and after medication in various stages of Parkinson's disease (PD). Methods: This prospective study included 60 patients with PD [Hoehn-Yahr (H-Y) stage 1-4] at the department of Neurology of Beijing Tsinghua Changgung Hospital, and 30 gender and age - matched healthy controls. The ReadyGo system was used to record gait parameters. The levodopa challenge test was applied to assess the therapeutic effect of medicine on gait. Results: We observed a shorter stride length and stride height, a longer stride time and turn-around time, and a reduction of stride speed in the PD group compared with the healthy control group significantly. No significant changes were noted in the variability of stride parameters (stride frequency variability and stride length variability). The radar chart demonstrated a gradual decline in gait parameters as the disease progressed. Compared to healthy control group, significant differences in stride speed and stride time were observed from H-Y stage 1 ( Conclusion: Gait changes can serve as a new early diagnosis marker for PD because of the early significant change in gait parameters especially on stride speed and stride time. As the disease advances, various gait parameters gradually deteriorate, suggesting that objective gait monitoring can provide a reference method to dynamically observe PD progression. Unlike the previous view that medicine has limited effect on gait, this study found that although the effect of medicine on gait is not as remarkable as that on tremor and rigidity, medicine can still effectively improve gait, especially in the patients with advanced PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.